key: cord-1046653-lz2zcjxp
authors: Rochette, Luc; Zeller, Marianne; Cottin, Yves; Vergely, Catherine
title: GDF15: an emerging modulator of immunity and a strategy in COVID-19 in association with iron metabolism
date: 2021-09-08
journal: Trends Endocrinol Metab
DOI: 10.1016/j.tem.2021.08.011
sha: 6a330fdaf0cfc1088b531dd08337f8818bcbca5a
doc_id: 1046653
cord_uid: lz2zcjxp

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic of respiratory and cardiovascular diseases, known as coronavirus disease 2019 (COVID-19). SARS-CoV-2 encodes structural proteins spike (S), E, M and N. The receptor-binding domain on the surface subunit S1 is responsible for attachment of the virus to angiotensin-converting enzyme 2 (ACE2). ACE2 is highly expressed in host cells. The cytokine storm observed in COVID-19 patients contributes to the endothelial vascular dysfunction, which can lead to acute respiratory distress syndrome, multiorgan failure, alteration in iron homeostasis, and death. Growth and differentiation factor 15 (GDF15), which belongs to the transforming growth factor-β (TGF-β) superfamily of proteins, plays a pivotal role in the development and progression of diseases because of its role as a metabolic regulator. In COVID-19, GDF15 activity increases in response to tissue damage. GDF15 appears to be a strong predictor of poor outcomes in critically COVID-19 patients and acts as an “inflammation-induced central mediator of tissue tolerance” via its metabolic properties. In this review, we will examine the potential properties of GDF15 as an emerging modulator of immunity in COVID-19 in association with iron metabolism. The virus life cycle in host cell provides potential targets for drug therapy.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a transmissible, pathogenic coronavirus that has caused a pandemic of acute respiratory diseases, now known as coronavirus disease 2019 . COVID-19 was first reported in Wuhan, China, in late December 2019, spreading rapidly to become a global pandemic. Cardiovascular and pulmonary complications are rapidly emerging as a major threat in COVID-19 in addition to respiratory disease. Compared with SARS-CoV-1, SARS-CoV-2 is more readily transmitted from human to human, spreading to multiple continents and leading to the declaration of a Public Health Emergency of International Concern [1] . Whole-genome sequencing identified a novel coronavirus: SARS-CoV-2. [2] . COVID-19 is characterized by 2 or 3 stages: about 80% of those infected experience 2 stages of illness beginning with an asymptomatic incubation period, followed by symptomatic illness lasting for several weeks. The third phase is characterized by severe respiratory illness, frequently accompanied by organ dysfunction. COVID-19 can lead to ARDS and has high morbidity and mortality. COVID-19 also affects the cardiovascular, renal, cerebrovascular, and blood coagulation systems [3] . Between the index case in early December 2019 and July 1, 2021, more than 180 million cases and 4 million deaths due to COVID-19 were reported worldwide.

SARS-CoV-2 is a member of the genus Betacoronavirus, similar to the coronaviruses that have caused previous pandemic diseases such as the Middle East respiratory syndrome coronavirus (MERS-CoV) [3, 4] . Coronaviruses, which are a large family of single-stranded enveloped RNA viruses, were not recognized as being particularly pathogenic in humans until the outbreak of SARS caused by SARS-CoV in 2002. Coronaviruses can be divided into four genera: α, β, γ, and δ, of which only α and β-coronaviruses are known to infect humans. Phylogenetic analyses have demonstrated that SARS-CoV-2 and SARS-CoV-1 are closely related, with a genomic percent identity at ~80%. SARS-CoV-2 has a positive-sense RNA genome that encodes 16 nonstructural proteins (NSPs), which are essential for replicative functions such as RNA polymerization by the RNA-dependent RNA polymerase, and four structural proteins. Coronaviruses have a crown-like morphology, consisting of these four structural proteins known as spike (S), envelope (E), membrane (M) and nucleocapsid (N) proteins. The viral genome surrounded by the N protein is a single-stranded RNA that is the genome [5, 6] . Coronavirus S proteins consist of three segments: an ectodomain, a singlepass transmembrane anchor, and an intracellular tail. The spike S is composed of two subunits S1 and S2. To engage a host cell receptor, the receptor-binding domain (RBD) of S1 undergoes hinge-like conformational movements that transiently hide or expose the determinants of receptor binding. The S protein contains two functional domains: the first is the RBD, and the second is a domain containing sequences that mediate the fusion of viral and cell membranes. It has been reported that the S protein contains a potential cleavage site for furin protease and a polybasic furin cleavage site (FCS). In COVID-19, FCS is reportedly linked to natural selection, and it appears that FCS is necessary for SARS-CoV-2 to infect human lung cells. Furin is transcriptionally induced by Notch1. The Notch family of receptors includes Notch-1, -2,-3, and -4. The interaction between the Notch receptor on one cell and the ligand on the adjacent cell results in conformational changes in the extracellular domain of the receptor, exposing a motif that is cleaved by "A Disintegrin and Metalloprotease 17" (ADAM17). Notch modulation can thus be considered a potential alternative approach to furin inhibition and ADAM17 upregulation. Therapeutics against SARS-CoV-2 should involve furin inhibitors [7] . (Figures 1a and 1b) 

Among structural proteins, the trimeric S protein has pivotal role in virus attachment and entry and disease pathogenesis. In SARS-CoVs, virus entry into the host cell is achieved by the viral S protein binding to angiotensin (Ang)-converting enzyme 2: ACE2 ( Figure 1 ). The S protein consists of two subunits: the S1 subunit, which contains a receptor-binding domain (RBD) that binds to ACE2 on the surface of host cells, and the S2 subunit, which mediates fusion between the membranes of the virus and the host cell. ACE2 is a transmembrane zinc metalloprotease that has 42% homology with ACE. In the classical renin-Ang system (RAS) cascade, the decapeptide Ang I is converted to Ang II by ACE, (kininase II), EC 3.4.15.1). There are two other peptidases: cathepsin A (carboxypeptidase A, lysosomal protective protein, deamidase, EC 3.4.16.5) and human homologue of ACE (ACE2). The angiotensin II type 1 receptor (AT1 receptor) is one of the key players in the RAS. The AT1 receptor promotes various intracellular signaling pathways through NADPH oxidase and reactive oxygen species (ROS) signaling [8] . (Figure 2) ACE2, like ACE, is a member of the M2 family of zinc metallopeptidases. It exists in a membrane-bound form and is widely expressed in a variety of mammalian tissues, including in the brain. ACE2 is an 805-amino-acid-long carboxypeptidase, with a 17-amino-acid Nterminal signal peptide and a C-terminal membrane anchor. ACE2 is a well-characterized negative regulator of the RAS system that converts AngII into the vasodilatory fragment Ang 1-7, simultaneously decreasing the AngII concentration to further facilitate the antihypertensive effect. Ang 1-7 activates the G-protein coupled MAS (mitochondrial assembly) receptor (MASR), inducing many beneficial cardiovascular effects including vasodilation, inhibition of cell growth, and anti-thrombotic effects.

The ACE2/Ang 1-7/MASR axis is known to have crucial roles in both the cardiovascular and the immune system, and the dysfunction of this pathway intensifies inflammation and contributes to impaired function in the inflamed tissue. ACE2 and MASR are highly expressed in the lungs, kidneys, heart and blood vessels. ACE2 expression is thought to be crucial for the biological mechanism underlying tissue-specific infection, and it is expressed primarily in alveolar epithelial type II cells in normal adult lungs. These cells produce surfactant proteins that reduce surface tension, preventing the alveoli from collapsing [9] . The expression of ACE2 in the heart and coronary arteries is even higher than in the lungs. Single-cell RNA sequencing data have also revealed that cardiomyocytes (especially those in the right ventricle) express ACE2 at a lower level than pericytes [10, 11] . A second protein that interacts with ACE2 is transmembrane protease serine 2 (TMPRSS2). TMPRSS2, as a transmembrane protease, is expressed in high levels in various organs. The process triggered by TMPRSS2 is the cleavage of S protein into S1 and S2 [12] . It is now demonstrated that SARS-CoV-2 uses ACE2 for cell-entry and that the TMPRSS2 protease has a critical role in SARS-CoV-2 cell entry. The steps that lead to virus entry are the following: 1) priming of Sprotein by TMPRSS2, which is necessary for the correct maturation of these proteins, and 2) formation of entry route into the cell through ACE2, resulting in virus entry.

The role of metalloproteinase domain 17 (ADAM17) in the progression of COVID-19 has recently been demonstrated. ADAMs are a Zn 2+ -dependent transmembrane and part of the secreted metalloprotease superfamily, so-called "molecular scissors". Like the other ADAMs, ADAM17 consists of an N-terminal signal sequence, a prodomain, a metalloprotease (or catalytic) domain, a disintegrin domain, a cysteine-rich region, a transmembrane region and a cytoplasmic tail. ( Figure 1b , Figure 2 ) Several lines of evidence suggest that lower expression of the ACE2 in membrane form (mACE2) and higher ADAM17 activity is associated with organ disease. ADAM17 proteinase is expressed in both the brain and peripheral organs, including the muscles, lungs, and heart. ADAM17 exists in two forms: pro-ADAM17, which is a full length protein (~100 KDa), and the mature form lacking its pro-domain (~80 KDa) [13] . Shedding of membrane proteins by ADAM proteases occur at the cell surface but also in exosomes. Currently, more than 80 substrates have been shown to be cleaved by ADAM17. Neutrophils and endothelial cells constitutively express ADAM17 on their surface. ADAM17, which is also known as tumor necrosis factor-a converting enzyme (TACE), is a membrane-bound enzyme that cleaves cell surface proteins, such as cytokines and adhesion proteins (e.g. L-selectin and ICAM-1). Activated endothelium upregulates the expression of these adhesion molecules and allows leukocytes to attach and migrate. The protease can also be activated in response to pathogen infection through Toll-like receptors (TLR); pathogens such as viruses and bacteria activate the ADAM17/epidermal growth factor receptor (EGFR) signaling pathway through TLR [14] . ADAM17 is believed to be the molecule responsible for uncontrolled IL-6 transsignaling, which increases pro-inflammatory responses during infection. This is because ADAM17 is crucial for membrane-bound IL-6R shedding; this action is implicated in the control of pro-and anti-inflammatory responses to viral antigenic stimuli [15] . dysfunction. In this context, pronounced endothelialitis (inflammation of the endothelium) and the recruitment of inflammatory cells has been demonstrated.

ACE2 counterbalances the vasoconstriction induced by activation of the ACE-Ang IIangiotensin receptor 1 (AT1) axis of the RAS (Figure 2 ). Overactivation of the ACE-Ang II-AT1 axis of the RAS and the endothelialitis caused by the viral infection promotes vasoconstriction, inflammation, and thrombosis in the vascular bed where it can cause various tissue injuries. This damage contributes to the mortality of a SARS-CoV-2 infection. Viral and inflammatory endothelialitis may play a key role in the pathogenesis of COVID-19. The associated thrombo-inflammation may explain the coagulopathy observed in COVID-19 patients and the high incidence of micro-and macro-thrombosis observed in the lungs and other organs, and endothelialitis contributes to the pathophysiology of the microcirculatory changes. The COVID-19 patients are at high risk for venous thromboembolism. The COVID-19 patients are showing varied coagulopathies and are at high risk for venous thromboembolisms (VTE). Thromboplasminflammation in COVID-19 coagulopathy consists of angiotensin II (Ang II)-induced coagulopathy, activated factor XII (FXIIa)-and kallikrein, kinin system-enhanced fibrinolysis, and disseminated intravascular coagulation (DIC) [16] . In addition, induction of apoptosis and pyroptosis might have an important role in endothelial cell injury in patients with COVID-19 [17] . The mechanisms of the viral and inflammatory endothelialitis remain incompletely elucidated and the direct infection of the endothelium by SARS-CoV2 is open to question. Viral protein was also found in endothelia of multiple organs of patients with persistent SARS-CoV2 infection [18] . The organs typically affected are lungs, kidneys, liver, heart, brain, and gastrointestinal tract.

The cytokine storm is a well-established clinical condition that is characterized by significant pro-inflammatory cytokine release leading to a dysregulated and hyperactive immune response. In COVID-19, the cytokine profile is characterized by increased interleukin (IL)-2, IL-6, IL-7, granulocyte macrophage colony-stimulating factor (GM-CSF), CC-chemokine ligand 2 (CCL2), interferon-γ (INF-γ) inducible protein 10, monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1-α (MIP 1-α), tumor necrosis factor-α (TNF-α), and the Notch pathway.

Furthermore, the cytokine storm observed in patients with severe COVID-19 contributes to further destruction of the endothelium, leading to ARDS, multiorgan failure, and death [19, 20] . The term "cytokine storm" was first coined in 1993 to describe a graft vs. host disease. The term has since been extended to describe the similar sudden cytokine releases associated with autoimmune diseases, sepsis, cancer, acute immunotherapy responses, and infectious diseases. The dysfunction and destruction of alveolar epithelia that are a consequence of viral infection of the respiratory epithelium increase the permeability of the capillary endothelium. It is important to underline differences between responses of the superficial subepithelial microcirculation, which is present all along the conducting airways, and the pulmonary microcirculation. An endothelial-epithelial co-operative is described and associated with an humoral defense [21] . These effects are mediated in part by the proinflammatory cytokines that are produced during the antiviral innate immune response. It has been reported that markers of systemic inflammation such as CRP and IL-6 are elevated in patients with poor outcomes. It is known that IL-6, via its soluble receptor (sIL-6R), initiates a pro-inflammatory response while an anti-inflammatory response is triggered by the membrane-bound IL-6 receptor (IL-6R). In addition, pro-inflammatory cytokines such as tumor necrosis factor α (TNF-α) and interferon -γ (IFN-γ) are highly upregulated in patients with COVID-19, leading to the cytokine storm and participating in cell death, and tissue and organ damage. TNF-α and IFN-γ cause an increase in nitric oxide (NO) production in endothelial cells via inducible NO synthase (iNOS) activity. This process has been proposed in COVID-19 infection. It has been demonstrated that NOS2 was significantly upregulated in patients with severe and critical COVID-19 [22] .It is not easy to precise the specific role of nitric oxide according to it can be cytotoxic or cytostatic depending upon the context [23] .

In vivo, the protection offered by neutralizing TNF-and IFN during SARS-CoV-2 infection suggest that inhibition of TNF-α and IFN-γ signaling and reduction of iNOS activity might be beneficial in "cytokine storm syndromes" such as COVID-19 [24] . Among the inductors of iNOS, lipopolysaccharides (LPS), a component of the outer cell wall of gram-negative bacteria, has the ability to elicit inflammatory response syndrome. There is a link between high LPS levels in the blood and metabolic syndrome that predisposes patients to severe COVID-19. Studies have also demonstrated an interaction between spike S protein and LPS that leads to intensified inflammation [25] .

Pathogenetic factors including innate immunity factors are involved in the induction of endothelialitis in COVID patients. The host immune system has multiple innate immune receptors, and innate immunity is a crucial component of preventing virus invasion. The suppressor of the cytokine signaling proteins (SOCS) family is one of the main regulators of the innate immune response. SOCS consist of eight intracellular proteins, SOCS1 to SOCS7. Cytokines activate the innate immune response and initiate a specific immune response against viruses, but dysregulation of host cytokine signaling during disease infection cause organ dysfunction. The SOCS family is a class of negative regulators induced by cytokines that can block the signal transduction of cytokines [26] . It has been demonstrated that SOCS1 and SOCS3 (SOCS1/3) function as virus induced intrinsic virulence factors [27] . There is considerable evidence that SOCS1 and SOCS3 play important roles in viral immune evasion involving a broad range of viruses. SOCS3 is expressed at a higher level in the obese patients who are at greater risk of the disease than are non-obese individuals.

It is reasonable to assume that the endothelium contributes to COVID-19-associated vascular inflammation, particularly endothelialitis in the lung, heart, and kidney. An inflammatory cascade in endothelial cells promotes leukocyte recruitment and oxidative stress. SARS-CoV-2, could trigger disruption of the balance between pro-oxidant and antioxidant mediators; J o u r n a l P r e -p r o o f Journal Pre-proof the magnitude of which could reflect the severity of infection and lung injury [28] (Figure 3 ) .Leukocyte transmigration is an important part of the inflammatory response involving oxidative stress and includes the recruitment of blood leukocytes, adhesion to the endothelial cell, and diapedesis. The accumulation of mononuclear cells in the small lung vessels is implicated in endothelial injury [17] . Earlier studies have shown that neutrophil extracellular traps (NET) may significantly contribute to virus-associated pathology. Histones are the main protein components of extracellular neutrophil traps and are known to have cytotoxic effects. The role of NETs is increasingly recognized as important factor of the respiratory diseases' pathogenesis. NETs consist of intracellular material that neutrophils organize in the cytoplasm, and then release when activated. Over-activation in anaphylatoxin-NET axis plays a pathological role in COVID-19 [29] .

Finally, in COVID-19 patients, hemodynamic changes associated with systemic inflammatory reactions and the pro-thrombotic environment contribute to the initiation and development of cardiovascular complications such as respiratory diseases and perhaps myocarditis [30] .

The incidence of typical viral myocarditis in COVID-19 positive patients appears low. In hearts of COVID-19 patients, the presence of an increased number of CD68+ cells suggests that COVID-19 may incite a form of myocarditis different from typical viral myocarditis, and associated with diffusely infiltrative cells of monocytes/macrophage lineage [31] .

The early evaluation and continued monitoring of these specific diseases are very important through the progression of COVID-19. The biomarkers of the inflammatory process represented by various cytokines and D-dimers may be also used to forecast the outcome of SARS-CoV-2 infection [32, 33] .

Understanding the profile of specific biomarkers and their variations as a function of different COVID-19 outcomes has been the aim of many studies. Morphological and metabolic disturbances of the heart during the COVID-19 are associated with elevated concentrations of cardiac blood biomarkers. Elevation of brain natriuretic peptide (BNP) or NT-proBNP is associated with worse outcomes among patients with ARDS. The determination of these biomarkers is very useful for diagnosis and prognosis [34] .

This would allow clinicians to use a stratified approach to the care of patients with COVID-19 disease according to their risk. In this approach, growth and differentiation factor 15 (GDF15) is a highly informative protein (Box 2)that may have considerable prognostic importance in COVID-19 patients (Box 3).

(NAG-1). GDF15 belongs to the transforming growth factor-β (TGF-β) superfamily of proteins. The TGF-secreted factor superfamily consists of more than 30 members, including a number of ligands including TGF-βs, activins, bone morphogenetic proteins (BMP), and GDFs. GDFs belong to the activing/myostatin (MSTN) subclass. The members of this subfamily have been named GDF1 through GDF15. TGF-β family proteins bind to distinct type I and type II serine/threonine kinase receptors. Signaling induced by the TGF family ligands are necessary for multiple processes during development, tissue homeostasis, and organ functioning [35, 36] . GDF15 is synthesized as a precursor protein: proGDF15. The mature protein is secreted as a homodimer linked by disulfide bonds and is released from the propeptide following intracellular cleavage. Mature GDF15 is soluble (sGDF15) and can be evaluated in blood. The mature peptide is an endogenous compound with a broad normal circulating range of ~0.15-1.15 ng/ml in healthy humans. GDF15 is widely expressed at different levels in human tissues. Various reports have shown the association of GDF15 with aging and longevity. GDF15 has been investigated for its contribution to ageing and agerelated cognitive decline.

In humans, GDF15 is widely expressed in skeletal muscle, and circulating GDF15 increases during exercise and during recovery from exercise. It is possible that GDF15 is secreted in response to cellular stress or injury in order to act locally [37] . GDF15 expression increases during many pathological conditions and serves as a marker of cellular stress and injury. GDF15 has multiple and even paradoxical roles within a pathological condition. Its effects can be dose-and time-related ,and dependent of the targeted tissues [38] . GDF15 acts as a "protective" cytokine, but, in certain conditions, GDF15 causes endothelial dysfunction by impairing vascular contraction and relaxation, potentially inducing microvascular disease and causing organ function to deteriorate [39] .

Research groups from different pharmaceutical companies simultaneously identified GDNFfamily receptor α-like (GFRAL) as the receptor for GDF15, signaling though the rearranged during transfection (RET) co-receptor. Alternatively, several laboratories have shown that both GDNF and GFRAL signal independently of RET [40] [41] [42] [43] .

As previously reported, several epidemiological studies have shown that GDF15 is associated with aging, and that the changes in GDF15 concentrations over time are predictors of allcause mortality. Several studies have found that inflammatory markers are elevated in the elderly and are associated with senescence. Senescence may be induced by various stimuli, and it is a complex stress response associated with a modification of expression of regulators, including GDF15 [44, 45] .

These findings indicate that, because of its function of metabolic regulator, GDF15 plays a pivotal role in the development and progression of diseases. GDF15 is expressed and secreted in response to oxidative stress and inflammation. Oxidative stress is closely associated with chronic inflammation and has a key role in the pathogenesis of vascular complications [46] . Studies have demonstrated that GDF15 is induced during sepsis and that it has a role in tissue protection, distinguishing GDF15 as an "inflammation-induced central mediator of tissue tolerance". In certain situations, GDFF15 takes on two opposing roles. The first implies the activation of GFRAL, inducing β-adrenergic signaling to stimulate the release of triglycerides from the liver. Cardio-protection is then achieved by maintaining triglyceride levels during acute inflammation [47] (Figure 3 ).

The direct effect of GDF15 on immune cells contributes to its ability to limit inflammationinduced damage. The protective mechanisms displayed by GDF15 through cellular reactions are multifactorial. GDF15 sometimes operates paradoxically in the regulation of immune responses and inflammation. It is thought to have a protective effect on various cardiovascular functions. These actions have been attributed to abnormal inflammation in response to systemic infection. Therefore, under abnormal physiological conditions, GDF15 appears to be protective, preventing the tissue damage that is associated with inflammation [48] .

As we reported previously, markers of systemic inflammation implicating CRP and IL-6 are elevated in patients with poor outcomes, and the origin of the dysregulated release of cytokines in COVID -19 has been ascribed to various factors. It is assumed that the viral replication that occurs during the onset of infection results in an elevated pro-inflammatory response. The "cytokine storm" (Box 1) produces an excessive inflammatory and immune response. While inflammation is vital for a healthy immune response, dysregulated inflammation can result in major damage to various organs. With ageing, the efficacy of the innate and adaptive immune response declines. This immunosenescence plays a central role in the age-related severity of COVID-19 [49, 50] .

Studies in humans have demonstrated that GDF15 activity increased under stress conditions in response to tissue damage, and that plasma GDF15 levels are higher in the elderly, perhaps in relation to the immunological outcome. It has been shown that GDF15 decreased the expression of pro-inflammatory cytokines and prevented the activation of T cells in the liver of mice with fibrosis, while deficiency of GDF15 aggravated hepatic injury [51] . The plasma levels of GDF15 increase with age and are inversely associated with active lifestyle. In particular, at any age, circulating GDF15 is significantly higher in inactive patients and significantly lower in active people, such as cyclists before the race, with respect to control subjects. The data indicate that GDF15 is associated with decreased muscle performance and increased inflammation [52] . GDF15 reduced the activation of pro-inflammatory factors, and prevented LPS-induced injury. Serum GDF15 levels are significantly increased in critically ill patients, associated with sepsis, organ failure, and disease severity .However, the function J o u r n a l P r e -p r o o f of GDF15 in sepsis remains unclear. Further research is required to examine the potential clinical importance of the preventive role of GDF15 against LPS-induced injury, and inflammatory response [53] .

Patients with hemorrhagic shock and encephalopathy syndrome (HSES) have a high early mortality rate, which may be caused by a cytokine storm. HSES and severe viral sepsis involving in COVID-19 situation appear to assign collective characteristics, including increased synthesis of cytokines, endothelial cell dysfunction, and coagulation abnormalities. Cytokines, and GDF15 levels were significantly higher in patients with HSES than in controls [54] . Finally, upon immune challenge, GDF15 through its immune-regulatory functions, has the potential to improve immunotherapies [55] . In this context; immunomodulatory therapies are now proposed for moderate the cytokine storm originated by COVID19 [56] .

Throughout the inflammatory process, complex interactions have been observed between GDF15 and enzymatic activities, erythropoiesis, iron metabolism, and hepcidin [57, 58] . Hepcidin, which regulates iron homeostasis, is stimulated by iron and inflammation but is suppressed by hypoxia and erythropoiesis. Erythropoiesis inhibits hepcidin synthesis, thereby promoting iron absorption and increasing the levels of available circulating iron. It has been demonstrated that hepcidin expression is suppressed by GDF15, thereby increasing iron availability for hemoglobin synthesis [59] . As a hypoxia effector molecule, GDF15 can be significantly up-regulated by anemia and hypoxia; as a signal molecule, it is associated with erythropoiesis and iron regulation. Finally, because it affects iron status, GDF15 might be involved in the pathogenesis of anemia in patients with cardiovascular disease. Considering the relationship between hepcidin metabolism and GDF15, it is reasonable to consider that GDF15 may potentially limit the availability of iron for hematopoiesis and provide an alternative explanation for the link with anemia. In elderly individuals with anemia, the observed elevation of GDF15 was correlated with kidney function. Recent studies have demonstrated the important role of GDF15 in cancer research, in particular for blood cancers. As described herein, GDF15 plays a significant role in erythropoiesis and regulates iron homeostasis via the modulation of hepcidin. In individuals with multiple myeloma (MM), GDF15 is abnormally secreted in marrow stromal cells. MM is a malignant condition that manifests with bone disease, renal failure and anemia. It has been demonstrated that the serum concentration of GDF15 in MM patients is positively correlated with the established prognostic factors of the disease, and that these concentrations were significantly higher in the studied patients with anemia and inversely correlated with blood hemoglobin and serum iron [60] . In hematologic malignancies, perturbations in iron availability are a major cause of anemia. Ferroptosis is recognized as iron-catalyzed excessive peroxidation of polyunsaturated fatty acid (PUFA)-containing phospholipids. Iron and lipid peroxidation are recognized as major mediators of ferroptosis. A recent report showed that the levels of GDF15 mRNA were increased during erastin-induced ferroptosis. GDF15 has J o u r n a l P r e -p r o o f also been investigated to clarify the relationship between GDF15 and iron metabolism implicating ferroptosis. A recent study using the human gastric cell line MGC803 showed that GDF15 knockdown promotes erastin-induced ferroptosis by attenuating the expression of SLC7A11, decreasing intracellular GSH levels and increasing peroxide levels [61] . Overall, these recent reports suggest that GDF15 plays a critical role in regulating ferroptosis and iron metabolism [62] .

Within hours of bacterial or viral infections, or other inflammatory stimuli, plasma iron concentrations decrease. This response is referred to as "hypoferremia of inflammation", and has been documented in humans. As we reported previously, the common mechanism in this type of inflammation is a cytokine-driven increase in hepcidin that downregulates ferroportin, thereby decreasing iron flow into extracellular fluid. Interestingly, most bacterial and viral infections increase hepcidin production in humans and mouse models. In COVID-19, the potential mechanisms behind the systemic clinical findings include dysregulated iron homeostasis resulting in oxidative stress and inflammatory response. The dysregulation of iron homeostasis and higher iron levels may support the progression of viral infections. Evaluating serum ferritin levels in COVID patients may therefore help to predict outcomes.

It has been suggested that GDF15 has the potential to significantly affect the outcome of a viral infection. The aim of a recent single-center retrospective study was to assess the levels of cytokines (IL-6 and IL-10), GDF15, and immunological markers in patients with confirmed COVID-19. When compared with controls, COVID-19 patients had higher levels of GDF15 (mean 12.4 ng/ml vs. <2 ng/ml) [63] . In a recent study: FHS (Framingham Heart Study) were evaluated associations among plasma biomarkers such as GDF15 and interstitial lung abnormalities (ILA) , and mortality in COVID patients. Causal inference analysis showed that the association of age with ILA and was likely mediated by GDF15 in the FHS. ILA progression was associated with an increased risk of death compared with those without ILA. After adjustment for ILA, age, sex, BMI, and current smoking, GDF15 remained associated with greater mortality [64] .

The aim of the COVID MECH study was to investigate the prognostic value of GDF15 in patients with laboratory-confirmed infection with SARS-CoV-2 and symptoms of COVID-19. GDF15 levels were correlated with the other inflammatory and cardiovascular biomarkers. GDF15 concentrations were associated with older age and higher CRP and D-dimer concentrations. The median baseline concentration of GDF15 in COVID patients was 2798 (1667-4528) pg/mL, and 79% of patients had GDF15 concentrations above age-specific standard values. GDF15 and ferritin remained associated with the endpoint of intensive care unit admission or death. Overall, GDF15 appeared to be a strong predictor of poor outcomes in critically ill COVID patients [65] . From two international cohorts of elderly patients with atrial fibrillation, recent data showed that GDF15 and other cardiovascular biomarkers such J o u r n a l P r e -p r o o f as NT-proBNP and hs-cTnT had the strongest associations with the sACE2 level. These results might be used to better identify individuals at risk of severe COVID-19 infection [66] .

Therapeutic approaches could be developed to target various phases of the virus' life cycle: adhesion and viral entry to host cell, viral protease, inhibition of the cytokine storm and protection of the organs. Recently it was reported that 1500 clinical trials related to COVID-19 have been registered, but for the moment none have found an optimal strategy [67] .

As reported here, COVID-19-endotheliitis could explain the systemic impaired microcirculatory function in different vascular beds and their clinical sequelae in patients with COVID-19. This hypothesis provides a rationale for therapies that protect the endothelium, such as common anti-inflammatory anti-cytokine drugs [68] or cardiovascular protectors such as ACE inhibitors and statins. However, preventive measures remain the best strategy in COVID-19, and several vaccines and monoclonal antibodies have been developed since the beginning of the pandemic. New clinical trials are exploring therapies that target the immune response and minimize the risk of a cytokine storm in COVID-19 [69] .

Endolysosomal function can thus be considered a target in COVID-19. As supported by recent clinical data, patients who have already taken lysosomotropic drugs for pre-existing conditions likely benefit from this treatment which prevents SARS-CoV-2 infection and transition to COVID-19 [70] . In these cellular environments, there are obvious changes in iron metabolism during SARS-CoV-2 infection. Increased iron levels and/or dysregulated iron homeostasis occur in several lung diseases, including pulmonary fibrosis. It could reasonably be considered that iron chelators prevent the development of pulmonary fibrosis and lung function disease following COVID-19 infection . In experimental and clinical studies, fibrosis and lung function decline are associated with pulmonary iron accumulation in bleomycininduced pulmonary fibrosis. In addition, iron accumulation is increased in lung sections from patients with idiopathic pulmonary fibrosis [71] . Several studies have assessed the potential anti-viral effect of iron-chelating therapy, and some trials (NCT04333550, NCT04361032) have attempted to evaluate the efficacy and safety of deferoxamine, a common iron chelator, in patients with COVID-19 [72] . Various studies have focused on better understanding the impact of antioxidants and the ways in which viral infections like COVID-19 infection disturb REDOX homeostasis. Current antioxidant agents of interest are enzymes (superoxide dismustases: SODs, GPXs), GSH, vitamins C, D, E, and B 6 , melatonin, minerals, selenium, N-acetylcysteine, quercetin, curcumin and naturally occurring polyphenols. More experimentations and larger clinical studies are need before any of these agents can be considered antiviral agents [73] .

Anti-inflammatory and immunosuppressive drugs have been tested as therapeutic regimens for pulmonary fibrosis, but none have been sufficiently effective in prolonging patient J o u r n a l P r e -p r o o f survival. Recombinant GDF15 could potentially be developed as a biopharmaceutical for treating pulmonary fibrosis. GDF15 demonstrated therapeutic effects in a mouse model of bleomycin-induced pulmonary fibrosis [74] . Perhaps an association with an additional antiviral drug is possible, and an association with the SOCS1/3 antagonist has been suggested in this perspective. The properties of SOCS1/3 could be harnessed pharmacologically as prophylactic and/or therapeutic mechanisms against COVID-19 infection [27] .

The ACE2/COVID-19 interface is also a promising therapeutic target [75] . Structure-based rational design of binders with enhanced affinities to either ACE2 or the S protein may accelerate development of decoy ligands or neutralizing antibodies in order to neutralize the viral infection [76] . Preclinical studies of neutralizing-antibody treatments for SARS-CoV-2 infection in several animal models have shown promising results. LY-CoV555 (also known as LY3819253), a potent antispike neutralizing monoclonal antibody that binds to the receptorbinding domain of SARS-CoV-2, was derived from convalescent plasma obtained from a Covid-19 patient. LY-CoV555 appeared to accelerate the natural decline in viral load over time [77] . To date, eight SARS-CoV-2 neutralizing antibodies have entered clinical evaluation -LY-CoV555, JS016, REGN-COV2, TY027, BRII-196, BRII-198, CT-P59, and SCTA01 [78] .

On the therapeutics side, another approach is the activation of the MAS receptor or the administration of Ang-(1-7) or MAS analogs, which could be important additive measures to control the inflammatory response mediated by SARS-CoV-2 [78] . Protective effects have been elicited in vivo by of Ang-(1-7) as well as by the MAS-receptor agonist AVE 0991 (C₂₉H₃₂N₄O₅S₂), which can reportedly mimic the effects of Ang-(1-7) [79] . (Figure 2) Because the protease TMPRSS2 is involved in SARS-CoV-2 cell entry, TMPRSS2 inhibitors might constitute a treatment option once they are tested and approved for clinical use. Camostat mesylate is a synthetic serine protease inhibitor that can inhibit the TMPRSS2 protein in lung cells. Nafamostat mesylate, another TMPRSS2 serine protease inhibitor, may also prevent the entry of virus into the host cell [80, 81] . Similarly, we previously reported that FCS was necessary for SARS-CoV-2 to infect human lung cells, and that therapeutics against SARS-CoV-2 should involve furin inhibitors. Synthetic furin inhibitors, such as MI-1851, decanoyl-RVKR-chloromethylketone (CMK) and naphthofluorescein, seem to be able to inhibit SARS-CoV-2 replication in human respiratory tract cells [7, [82] [83] [84] . In conclusion, a list of currently available drugs, their possible mechanisms of action, and the strategies that could be used to treat COVID-19 patients are being investigated in in pre-clinical and clinical trials [85] (Table 1) . Several biomedical research laboratories are currently testing a variety of possible treatments in order to determine their efficacy and to identify the approaches with the most promise [86] . The receptor-binding domain on the surface subunit S1 of the trimeric S protein is responsible for attachment of the virus to angiotensin (Ang)-converting enzyme 2 (ACE2). Priming of the spike protein by transmembrane serine protease 2 (TMPRSS2), a cell membrane-bound protease, is an essential step for cell entry by the virus. b) Furin pre-cleaves spike proteins at the S1/S2 site and promotes subsequent TMPRSS2dependent entry into host cells. Cell membrane receptor angiotensin-converting enzyme 2 (ACE2) mediates entry of SARS-CoV-2. The spikes interact with ACE2 through a receptor binding domain (RBD). ADAM17 is a membrane-bound enzyme that cleaves cell surface proteins, such as ACE2. MPRSS2 competes with the metalloprotease ADAM17 for ACE2 processing.

J o u r n a l P r e -p r o o f Angiotensin (Ang)-II is formed from the cleavage of Ang-I by angiotensin converting enzyme (ACE). Ang-II binds to Ang-II type 1 (AT1R), and type 2 (AT2R) receptors. Angiotensin converting enzyme type 2 (ACE-2) is a monocarboxypeptidase homologous to ACE whose active site is exposed at the extracellular surface. Ang II can be hydrolyzed into Ang (1-7) through the actions of ACE2. The polypeptide Ang I can be converted into Ang (1-7) by the actions of neprilysin (NEP). Ang-(1-7) activates the G-protein coupled Mas (mitochondrial assembly) receptor (MASR). The soluble form of ACE2 (sACE2) circulates in the blood.

In COVID-19 (SARS-CoV-2) the proinflammatory response and the cytokine storm represent the cornerstone of COVID-19 pathogenesis, inducing critical incidences for the host. A cytokine profile in COVID-19 is characterized by increased of various endogenous compounds such as interleukin (IL) -6, IL-10, tumor necrosis factor-α (TNF-α) and the Notch 1-4 pathway. The suppressor of the cytokine signaling proteins (SOCS 1/3) regulate the immune response.

J o u r n a l P r e -p r o o f During COVID-19, GDF15 is induced and takes into a tissue-protective effect notifying GDF15 as an "inflammation-induced central mediator of tissue tolerance". Cellular stress, and chronic inflammation associated with COVID-19 infection induce the secretion and the release of GDF15 which appears in the blood to target specific receptors. GDF15 binds to GDNF-family receptor α-like (GFRAL) in the brain. GDF15 exerts direct effects on immune cells independent of centrally regulated mechanisms and has the potential to affect the outcome of COVID-19 infection as an emerging modulator of immune responses. GDF15-GFRAL complex mediates regulation of central and peripheral functions, resulting in activation of nitric oxide synthase (NOS) , PI3K/AKT, nuclear factor κB (NFκB)and the forkhead box (FOX) transcription factors: Foxo3 pathways. These pathways are essential in regulating cellular controls on tissue homeostasis and anti-inflammatory effects.

SARS-CoV-2, could trigger disruption of the balance between pro-oxidant and antioxidant mediators; the magnitude of the oxidative stress could reflect the severity of infection and lung injury. Liver J o u r n a l P r e -p r o o f injury is common in patients with COVID-19. Interactions exist during inflammatory process, oxidative stress, iron metabolism and hepatic functions through ferritin and hepcidin properties. Moreover, "labile iron" can promote inflammation by increased production of reactive oxygen species (ROS). Insulin-like growth factor 1 (IGF1) synthesized primarily in the liver acts as an important modulator of cellular functions. Growth hormone (GH) secreted from the pituitary gland sends signals to the liver to stimulate the production of IGF1. Circulating GDF15 levels influence the liver to inhibit the actions of GH. COVID19-associated multiorgan failure is linked to impaired mitochondrial function. Mitochondria localization may be necessary for SARS-CoV-2 replication.

J o u r n a l P r e -p r o o f

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

A new coronavirus associated with human respiratory disease in China

COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Origin and evolution of pathogenic coronaviruses

Emerging coronaviruses: Genome structure, replication, and pathogenesis

Delving deep into the structural aspects of a furin cleavage site inserted into the spike protein of SARS-CoV-2: A structural biophysical perspective

Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets?

SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes

Cells of the adult human heart

The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin

Expression of ACE2, the SARS-CoV-2 Receptor, and TMPRSS2 in Prostate Epithelial Cells

ADAM17: a molecular switch to control inflammation and tissue regeneration

Multiple TLRs activate EGFR via a signaling cascade to produce innate immune responses in airway epithelium

Decoding the enigma of antiviral crisis: Does one target molecule regulate all?

Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies

Endothelial cell infection and endotheliitis in COVID-19

Identification of Immunohistochemical Reagents for In Situ Protein Expression Analysis of Coronavirus-associated Changes in Human Tissues

On the Alert for Cytokine Storm: Immunopathology in COVID-19

COVID-19: the vasculature unleashed

Early humoral defence: Contributing to confining COVID-19 to conducting airways?

Does eNOS derived nitric oxide protect the young from severe COVID-19 complications?

Inflammation and Its Role in Regeneration and Repair

Synergism of TNF-alpha and IFN-gamma Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes

SARS-CoV-2 spike protein binds to bacterial lipopolysaccharide and boosts proinflammatory activity

SOCS Proteins Participate in the Regulation of Innate Immune Response Caused by Viruses

SOCS, Intrinsic Virulence Factors, and Treatment of COVID-19

Upregulation of oxidative stress gene markers during SARS-COV-2 viral infection

Defective NET clearance contributes to sustained FXII activation in COVID-19-associated pulmonary thrombo-inflammation

Cardiovascular Manifestations and Mechanisms in Patients with COVID-19

COVID-19 Myocarditis: Quantitative analysis of the inflammatory infiltrate and a proposed mechanism

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

Covid-19: The Rollercoaster of Fibrin(Ogen), D-Dimer, Von Willebrand Factor, P-Selectin and Their Interactions with Endothelial Cells

The prognostic effect of brain natriuretic peptide levels on outcomes of hospitalized patients with COVID-19

The multiple facets of the TGF-beta family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1

Growth and differentiation factor 11 (GDF11): Functions in the regulation of erythropoiesis and cardiac regeneration

Exercise increases circulating GDF15 in humans

Role of Growth Differentiation Factor 15 in Lung Disease and Senescence: Potential Role Across the Lifespan

Growth differentiation factor 15 impairs aortic contractile and relaxing function through altered caveolar signaling of the endothelium

GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates

The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL

Growth Differentiation Factor 15 May Predict Mortality of Peripheral and Coronary Artery Diseases and Correlate with Their Risk Factors

Insights Into Mechanisms of GDF15 and Receptor GFRAL: Therapeutic Targets

Senescence in Health and Disease

Secreted growth differentiation factor 15 as a potential biomarker for mitochondrial dysfunctions in aging and age-related disorders

Redox Functions of Heme Oxygenase-1 and Biliverdin Reductase in Diabetes

GDF15 Is an Inflammation-Induced Central Mediator of Tissue Tolerance

Growth differentiation factor-15 and its role in diabetes and cardiovascular disease

Age-associated changes in human CD4(+) T cells point to mitochondrial dysfunction consequent to impaired autophagy

Inflammaging: a new immune-metabolic viewpoint for age-related diseases

GDF15 deficiency exacerbates chronic alcohol-and carbon tetrachlorideinduced liver injury

GDF15 Plasma Level Is Inversely Associated With Level of Physical Activity and Correlates With Markers of Inflammation and Muscle Weakness

GDF-15 prevents lipopolysaccharide-mediated acute lung injury via upregulating SIRT1

Elevated cytokine, chemokine, and growth and differentiation factor-15 levels in hemorrhagic shock and encephalopathy syndrome: A retrospective observational study

Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint

COVID-19: In the Eye of the Cytokine Storm

Iron, oxidative stress, and redox signaling in the cardiovascular system

The iron-regulatory hormone hepcidin: a possible therapeutic target?

Reciprocal regulation between hepcidin and erythropoiesis and its therapeutic application in erythroid disorders

Evaluating the Relationship of GDF-15 with Clinical Characteristics, Cardinal Features, and Survival in Multiple Myeloma

GDF15 knockdown promotes erastin-induced ferroptosis by decreasing SLC7A11 expression

The Application of Ferroptosis in Diseases

Pro-and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study

The Association of Aging Biomarkers, Interstitial Lung Abnormalities, and Mortality

Growth Differentiation Factor 15 Provides Prognostic Information Superior to Established Cardiovascular and Inflammatory Biomarkers in Unselected Patients Hospitalized With COVID-19

Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation

Combating the Pandemic COVID-19: Clinical Trials, Therapies and Perspectives

Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed

Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts

COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks

Critical role for iron accumulation in the pathogenesis of fibrotic lung disease

Corona (COVID-19) time musings: Our involvement in COVID-19

pathogenesis, diagnosis, treatment and vaccine planning

Role of Oxidative Stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) Infection: A Review

Epithelial cell-derived cytokines CST3 and GDF15 as potential therapeutics for pulmonary fibrosis

Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2

AVE0991, a Nonpeptide Angiotensin 1-7 Receptor Agonist, Improves Glucose Metabolism in the Skeletal Muscle of Obese Zucker Rats: Possible Involvement of Prooxidant/Antioxidant Mechanisms

Priming of SARS-CoV-2 S protein by several membrane-bound serine proteinases could explain enhanced viral infectivity and systemic COVID-19 infection

Candidate drugs against SARS-CoV-2 and COVID-19

TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells

Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects

Furin: A Potential Therapeutic Target for COVID-19

Can Activation of NRF2 Be a Strategy against COVID-19?

Evaluation of mechanisms of action of re-purposed drugs for treatment of COVID-19

Molecular Mechanism of Action of Repurposed Drugs and Traditional Chinese Medicine Used for the Treatment of Patients Infected With COVID-19: A Systematic Scoping Review

Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy

Clinical Management of COVID-19: A Review of Pharmacological Treatment Options

Modeling of SARS-CoV-2 Treatment Effects for Informed Drug Repurposing

This work was supported by grants from the Agence Nationale pour la Recherche (ANR SMOG-15, ANR-19-CE17-0009), the French Ministry of Research, and from the Regional Council of Bourgogne -Franche-Comté, FEDER and Association de Cardiologie de Bourgogne. The authors wish to thank Suzanne Rankin for revising the English.J o u r n a l P r e -p r o o f

L.R. and C.V. wrote the manuscript. M.Z. and Y.C. provided significant contribution to the content of the manuscript.

The authors declare that there are no conflicts of interest.

ADAM17: (disintegrin and metalloproteinase-17) or tumor necrosis factor-a converting enzyme (TACE), is a membrane-bound enzyme that cleaves cell surface proteins, such as cytokines and adhesion proteins.Apoptosis: apoptosis is a process of programmed cell death, characterized by distinct morphological characteristics and energy-dependent biochemical mechanisms. 

Endothelialitis: is an inflammation of the endothelium; contributing to the pathophysiology of the microcirculatory changes.